Antibodies are essential tools for both basic and clinical research. However, there has been growing distrust of commercially available antibodies with regard to specificity and performance variability. As a result, the research community and funding agencies have demanded that antibody suppliers increase their efforts to more thoroughly validate these reagents. One approach to address this is through knockout or knockdown of the target protein by CRISPR- or RNAi-mediated technologies.

Learn more about the CRISPR/Cas9 technology
Learn more about the knockdown technology

In support of this goal, GeneTex is conducting knockout/knockdown-based validation as a fundamental component of its antibody quality assurance process. To date, we have evaluated over one thousand of our most popular products covering multiple research topics, such as apoptosis, metabolism, epithelial–mesenchymal transition, and neurodegenerative diseases. We will continue to expand these efforts in the future. Antibodies that have passed the KO/KD test will be labeled with the KO/KD validated icon.